Lilly expands Purdue University collab with up to a $250 million investment
US pharma major Eli Lilly (NYSE: LLY) announced a significant expansion of its long-standing alliance with Purdue University, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.
This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the USA, will seek to accelerate innovation at every stage of the pharmaceutical pipeline, the company noted.
There is a lot of uncertainty around federal research funding at the moment due to President Donald Trump’s decision to cut such funding, so landing what could be the largest-ever agreement of its kind between private industry and a university is a big deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze